Michigan-based precision medicine start-up Strata Oncology has raised $26m in a series B funding round led by Pfizer Ventures and the Merck Global Health Innovation Fund. The company is developing an innovative treatment for patients with advanced melanoma, which can be deadly if left untreated. Rhodes said Strata was also integrating its data with telehealth platforms to better monitor patient outcomes.
Michigan-based precision medicine start-up Strata Oncology has raised $26m in a series B funding round led by Pfizer Ventures and the Merck Global Health Innovation Fund. The cash injection will allow the company to expand its precision oncology network, and, according to CEO Dan Rhodes, "take on the conduct of drug trials" and broaden the use of treatments among genetically similar cancers. Rhodes said Strata was also integrating its data with telehealth platforms to better monitor patient outcomes.